Eris Lifesciences Acquires Velbiom's Probiotic Portfolio for Rs 50 Crore

Written By :  Parthika Patel
Published On 2026-03-23 09:30 GMT   |   Update On 2026-03-23 09:30 GMT

Mumbai: Eris Lifesciences Limited has announced the acquisition of the branded probiotic business of Velbiom Probiotics Private Limited through a slump sale deal valued at Rs 50 crore.

The decision was approved during the company’s Board of Directors meeting held on March 20, 2026.

The acquisition has been executed via a Business Transfer Agreement (BTA), marking Eris Lifesciences’ strategic expansion into the growing probiotics and microbiome-based therapeutics segment. Velbiom Probiotics is recognized as a science-driven bio-therapeutics company focused on India-specific microbiome research and therapy development.

According to the disclosed details, the acquired portfolio includes a range of prebiotic and probiotic formulations targeting metabolic health, gut wellness, and women’s health. The business has demonstrated steady financial performance, reporting revenues of ₹19.64 crore in FY25, ₹17.56 crore in FY24, and ₹16.02 crore for the first nine months of FY26.

Eris Lifesciences clarified that the transaction does not involve any related party and has been conducted at arm’s length. Additionally, no shareholding exchange or special rights such as board appointments are associated with the agreement.

The company stated that the acquisition aligns with its long-term strategy to strengthen its presence in specialty and chronic therapy segments, particularly in emerging areas like microbiome-based healthcare solutions.

Also Read: Eris Gets CDSCO Panel Nod To Dapagliflozin-Bisoprolol-Sacubitril Valsartan Combo Kit, Phase IV Trial Mandated

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News